The Intestinal Microbiota in Chronic Liver Disease

Advances in Immunology

Volumn 117, Issue , 2013, Pages 73-97

  Henao Mejia, Jorge ^a   Elinav, Eran ^b   Thaiss, Christoph A ^b   Flavell, Richard A ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Inflammasomes; Innate immunity; Liver; Microbiota; Toll like receptors

Indexed keywords

INFLAMMASOME; INTERFERON REGULATORY FACTOR 7; LECTIN; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ARTICLE; AUTOIMMUNE LIVER DISEASE; BACTERIAL OVERGROWTH; BACTEROIDES; BIFIDOBACTERIUM; CALORIC INTAKE; CHRONIC LIVER DISEASE; COMORBIDITY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; ENTERITIS; ENTEROBACTERIACEAE; FIRMICUTES; HEPATIC ENCEPHALOPATHY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; INTESTINE FLORA; LACTOBACILLUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 84876699656     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410524-9.00003-7     Document Type: Chapter

References (118)

1. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
2. Bajaj J.S. Review article: The modern management of hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2010, 31:537-547.
3. Bajaj J.S., Heuman D.M., Wade J.B., Gibson D.P., Saeian K., Wegelin J.A., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140:478-487. e471.
4. Bajaj J.S., Ridlon J.M., Hylemon P.B., Thacker L.R., Heuman D.M., Smith S., et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012, 302:G168-G175.
5. Bambha K., Kim W.R., Talwalkar J., Torgerson H., Benson J.T., Therneau T.M., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
6. Basile A.S., Jones E.A. Ammonia and GABA-ergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997, 25:1303-1305.
7. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., et al. Rifaximin treatment in hepatic encephalopathy. The New England Journal of Medicine 2010, 362:1071-1081.
8. Bauer T.M., Steinbruckner B., Brinkmann F.E., Ditzen A.K., Schwacha H., Aponte J.J., et al. Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. The American Journal of Gastroenterology 2001, 96:2962-2967.
9. Bergquist A., Montgomery S.M., Bahmanyar S., Olsson R., Danielsson A., Lindgren S., et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology 2008, 6:939-943.
10. Boaru S.G., Borkham-Kamphorst E., Tihaa L., Haas U., Weiskirchen R. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. Journal of Inflammation (London) 2012, 9:49.
11. Bogdanos D.P., Baum H., Grasso A., Okamoto M., Butler P., Ma Y., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. Journal of Hepatology 2004, 40:31-39.
12. Bogdanos D.P., Baum H., Okamoto M., Montalto P., Sharma U.C., Rigopoulou E.I., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 2005, 42:458-465.
13. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
14. Campillo B., Pernet P., Bories P.N., Richardet J.P., Devanlay M., Aussel C. Intestinal permeability in liver cirrhosis: Relationship with severe septic complications. European Journal of Gastroenterology & Hepatology 1999, 11:755-759.
15. Carter B.A., Karpen S.J. Intestinal failure-associated liver disease: Management and treatment strategies past, present, and future. Seminars in Liver Disease 2007, 27:251-258.
16. Carvalho F.A., Aitken J.D., Vijay-Kumar M., Gewirtz A.T. Toll-like receptor-gut microbiota interactions: Perturb at your own risk!. Annual Review of Physiology 2012, 74:177-198.
17. Cerda C., Perez-Ayuso R.M., Riquelme A., Soza A., Villaseca P., Sir-Petermann T., et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Journal of Hepatology 2007, 47:412-417.
18. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain?. Hepatology 2008, 47:1431-1433.
19. Chen Y., Yang F., Lu H., Wang B., Lei D., Wang Y., et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011, 54:562-572.
20. Claesson M.J., Jeffery I.B., Conde S., Power S.E., O'Connor E.M., Cusack S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012, 488:178-184.
21. Corrodi P. Jejunoileal bypass: Change in the flora of the small intestine and its clinical impact. Reviews of Infectious Diseases 1984, 6(Suppl. 1):S80-S84.
22. Csak T., Ganz M., Pespisa J., Kodys K., Dolganiuc A., Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
23. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
24. Day C.P., James O.F. Steatohepatitis: A tale of two " hits" ?. Gastroenterology 1998, 114:842-845.
25. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullet J.B., Massart S., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:14691-14696.
26. DuPont A.W., DuPont H.L. The intestinal microbiota and chronic disorders of the gut. Nature Reviews. Gastroenterology & Hepatology 2011, 8:523-531.
27. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
28. Elinav E., Strowig T., Kau A.L., Henao-Mejia J., Thaiss C.A., Booth C.J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
29. Figueroa L., Xiong Y., Song C., Piao W., Vogel S.N., Medvedev A.E. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. The Journal of Immunology 2012, 188:4506-4515.
30. Ganz M., Csak T., Nath B., Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World Journal of Gastroenterology 2011, 17:4772-4778.
31. Gao B., Seki E., Brenner D.A., Friedman S., Cohen J.I., Nagy L., et al. Innate immunity in alcoholic liver disease. American Journal of Physiology. Gastrointestinal and Liver Physiology 2011, 300:G516-G525.
32. Gross O., Gewies A., Finger K., Schafer M., Sparwasser T., Peschel C., et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 2006, 442:651-656.
33. Guarner C., Soriano G. Spontaneous bacterial peritonitis. Seminars in Liver Disease 1997, 17:203-217.
34. Gunnarsdottir S.A., Sadik R., Shev S., Simren M., Sjovall H., Stotzer P.O., et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. The American Journal of Gastroenterology 2003, 98:1362-1370.
35. Hashimoto E., Ideta M., Taniai M., Watanabe U., Okuda H., Nagasako K., et al. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. Journal of Gastroenterology and Hepatology 1993, 8:146-149.
36. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
37. Henao-Mejia J., Elinav E., Strowig T., Flavell R.A. Inflammasomes: Far beyond inflammation. Nature Immunology 2012, 13:321-324.
38. Hjelkrem M.C., Torres D.M., Harrison S.A. Nonalcoholic fatty liver disease. Minerva Medica 2008, 99:583-593.
39. Hopf U., Moller B., Stemerowicz R., Lobeck H., Rodloff A., Freudenberg M., et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. The Lancet 1989, 2:1419-1422.
40. Hosel M., Broxtermann M., Janicki H., Esser K., Arzberger S., Hartmann P., et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012, 55:287-297.
41. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306.
42. Husova L., Lata J., Husa P., Senkyrik M., Jurankova J., Dite P. Bacterial infection and acute bleeding from upper gastrointestinal tract in patients with liver cirrhosis. Hepato-Gastroenterology 2005, 52:1488-1490.
43. Iliev I.D., Funari V.A., Taylor K.D., Nguyen Q., Reyes C.N., Strom S.P., et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012, 336:1314-1317.
44. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. The Journal of Clinical Investigation 2009, 119:305-314.
45. Janse M., Lamberts L.E., Franke L., Raychaudhuri S., Ellinghaus E., Muri Boberg K., et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011, 53:1977-1985.
46. Joo M., Abreu-e-Lima P., Farraye F., Smith T., Swaroop P., Gardner L., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: A case-control study. The American Journal of Surgical Pathology 2009, 33:854-862.
47. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nature Immunology 2010, 11:373-384.
48. Kerrigan A.M., Brown G.D. Syk-coupled C-type lectins in immunity. Trends in Immunology 2011, 32:151-156.
49. Latz E. The inflammasomes: Mechanisms of activation and function. Current Opinion in Immunology 2010, 22:28-33.
50. Lech M., Susanti H.E., Rommele C., Grobmayr R., Gunthner R., Anders H.J. Quantitative expression of C-type lectin receptors in humans and mice. International Journal of Molecular Sciences 2012, 13:10113-10131.
51. Levy C., Lindor K.D. Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis. Seminars in Liver Disease 2006, 26:22-30.
52. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11070-11075.
53. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
54. Li L., Chen L., Hu L., Liu Y., Sun H.Y., Tang J., et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
55. Lin Y., Yu L.X., Yan H.X., Yang W., Tang L., Zhang H.L., et al. Gut-derived lipopolysaccharide promotes T-cell-mediated hepatitis in mice through Toll-like receptor 4. Cancer Prevention Research (Philadelphia, PA) 2012, 5:1090-1102.
56. Liu Q., Duan Z.P., Ha D.K., Bengmark S., Kurtovic J., Riordan S.M. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
57. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
58. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings 1980, 55:434-438.
59. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
60. Maynard C.L., Elson C.O., Hatton R.D., Weaver C.T. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489:231-241.
61. Michelsen K.S., Arditi M. Toll-like receptors and innate immunity in gut homeostasis and pathology. Current Opinion in Hematology 2007, 14:48-54.
62. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
63. Miyake Y., Yamamoto K. Role of gut microbiota in liver diseases. Hepatology Research 2013, 43(2):139-146.
64. Muegge B.D., Kuczynski J., Knights D., Clemente J.C., Gonzalez A., Fontana L., et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011, 332:970-974.
65. Mueller T., Beutler C., Pico A.H., Shibolet O., Pratt D.S., Pascher A., et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver International 2011, 31:1574-1588.
66. Mulder A.H., Horst G., Haagsma E.B., Limburg P.C., Kleibeuker J.H., Kallenberg C.G. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993, 17:411-417.
67. Nardone G., Compare D., Liguori E., Di Mauro V., Rocco A., Barone M., et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010, 299:G669-G676.
68. Nazim M., Stamp G., Hodgson H.J. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepato-Gastroenterology 1989, 36:349-351.
69. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease 2010, 42(Suppl. 3):S206-S214.
70. O'Toole A., Alakkari A., Keegan D., Doherty G., Mulcahy H., O'Donoghue D. Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2012, 10:439-441.
71. Osman N., Adawi D., Ahrne S., Jeppsson B., Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Digestive and Liver Disease 2007, 39:849-856.
72. Pappo I., Bercovier H., Berry E.M., Haviv Y., Gallily R., Freund H.R. Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide. Journal of Parenteral and Enteral Nutrition 1992, 16:529-532.
73. Petrasek J., Dolganiuc A., Csak T., Kurt-Jones E.A., Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 2011, 140:697-708. e694.
74. Petrasek J., Dolganiuc A., Csak T., Nath B., Hritz I., Kodys K., et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011, 53:649-660.
75. Propst A., Propst T., Judmaier G., Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology 1995, 108:1607.
76. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
77. Quigley E.M., Marsh M.N., Shaffer J.L., Markin R.S. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993, 104:286-301.
78. Ritter M., Gross O., Kays S., Ruland J., Nimmerjahn F., Saijo S., et al. Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:20459-20464.
79. Rudolph G., Gotthardt D., Kloters-Plachky P., Kulaksiz H., Rost D., Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. Journal of Hepatology 2009, 51:149-155.
80. Sabate J.M., Jouet P., Harnois F., Mechler C., Msika S., Grossin M., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obesity Surgery 2008, 18:371-377.
81. Sajjad A., Mottershead M., Syn W.K., Jones R., Smith S., Nwokolo C.U. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2005, 22:291-299.
82. Sancho D., Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annual Review of Immunology 2012, 30:491-529.
83. Sano H., Nakazawa T., Ando T., Hayashi K., Naitoh I., Okumura F., et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. Journal of Hepato-Biliary-Pancreatic Sciences 2011, 18:154-161.
84. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
85. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nature Medicine 2007, 13:1324-1332.
86. Selmi C., Balkwill D.L., Invernizzi P., Ansari A.A., Coppel R.L., Podda M., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
87. Sheth S.G., Gordon F.D., Chopra S. Nonalcoholic steatohepatitis. Annals of Internal Medicine 1997, 126:137-145.
88. Shimada M., Hashimoto E., Taniai M., Hasegawa K., Okuda H., Hayashi N., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology 2002, 37:154-160.
89. Sidhu S.S., Goyal O., Mishra B.P., Sood A., Chhina R.S., Soni R.K. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). The American Journal of Gastroenterology 2011, 106:307-316.
90. Slack E., Hapfelmeier S., Stecher B., Velykoredko Y., Stoel M., Lawson M.A., et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009, 325:617-620.
91. Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature 2012, 481:278-286.
92. Sung J.Y., Shaffer E.A., Costerton J.W. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Digestive Diseases and Sciences 1993, 38:2104-2112.
93. Terjung B., Herzog V., Worman H.J., Gestmann I., Bauer C., Sauerbruch T., et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332-340.
94. Terjung B., Sohne J., Lechtenberg B., Gottwein J., Muennich M., Herzog V., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59:808-816.
95. Thalheimer U., Triantos C.K., Samonakis D.N., Patch D., Burroughs A.K. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005, 54:556-563.
96. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Konigsrainer A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. The Journal of Nutrition 2008, 138:1452-1455.
97. Tolman K.G., Fonseca V., Dalpiaz A., Tan M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007, 30:734-743.
98. Tremaroli V., Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489:242-249.
99. Tsutsui H., Imamura M., Fujimoto J., Nakanishi K. The TLR4/TRIF-mediated activation of NLRP3 inflammasome underlies endotoxin-induced liver injury in mice. Gastroenterology Research and Practice 2010, 2010:641865.
100. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
101. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
102. Ubeda C., Lipuma L., Gobourne A., Viale A., Leiner I., Equinda M., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. The Journal of Experimental Medicine 2012, 209:1445-1456.
103. Vanderhoof J.A., Tuma D.J., Antonson D.L., Sorrell M.F. Effect of antibiotics in the prevention of jejunoileal bypass-induced liver dysfunction. Digestion 1982, 23:9-15.
104. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
105. Visvanathan K., Skinner N.A., Thompson A.J., Riordan S.M., Sozzi V., Edwards R., et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45:102-110.
106. Wang A.P., Migita K., Ito M., Takii Y., Daikoku M., Yokoyama T., et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. Journal of Autoimmunity 2005, 25:85-91.
107. Wang B., Trippler M., Pei R., Lu M., Broering R., Gerken G., et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. Journal of Hepatology 2009, 51:1037-1045.
108. Washington M.K. Autoimmune liver disease: Overlap and outliers. Modern Pathology 2007, 20(Suppl. 1):S15-S30.
109. Watanabe A., Sohail M.A., Gomes D.A., Hashmi A., Nagata J., Sutterwala F.S., et al. Inflammasome-mediated regulation of hepatic stellate cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 296:G1248-G1257.
110. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
111. Williams R. Review article: Bacterial flora and pathogenesis in hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 2007, 25(Suppl. 1):17-22.
112. Williams C.D., Farhood A., Jaeschke H. Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury. Toxicology and Applied Pharmacology 2010, 247:169-178.
113. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
114. Xie N., Cui Y., Yin Y.N., Zhao X., Yang J.W., Wang Z.G., et al. Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. BMC Complementary and Alternative Medicine 2011, 11:53.
115. Ye B.D., Yang S.K., Boo S.J., Cho Y.K., Yang D.H., Yoon S.M., et al. Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea. Inflammatory Bowel Diseases 2011, 17:1901-1906.
116. Yokoyama T., Komori A., Nakamura M., Takii Y., Kamihira T., Shimoda S., et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver International 2006, 26:467-476.
117. Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical Gastroenterology and Hepatology 2011, 9:524-530. e521; quiz e560.
118. Zhu P., Duan L., Chen J., Xiong A., Xu Q., Zhang H., et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Human Gene Therapy 2011, 22:853-864.